Linked Life Data

15950494

Source:http://linkedlifedata.com/resource/pubmed/id/15950494

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
2005-7-25
pubmed:abstractText
Direct block of I(Kr) by non-antiarrhythmic drugs (NARDs) is a major cause of QT prolongation and torsades de pointes (TdP), and has made the hERG potassium channel a major target of drug safety programs in cardiotoxicity. Block of hERG currents is not the only way that drugs can adversely impact the repolarizing current I(Kr), however. We have shown recently that two drugs in clinical use do not block hERG but produce long QT syndrome (LQTS) and TdP by inhibiting trafficking of hERG to the cell surface. To address the need for an inexpensive, rapid, and comprehensive assay to predict both types of hERG risk early in the drug development process, we have developed a novel antibody-based chemiluminescent assay called HERG-Lite.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1056-8719
pubmed:author
pubmed:issnType
Print
pubmed:volume
52
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
136-45
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:articleTitle
HERG-Lite: a novel comprehensive high-throughput screen for drug-induced hERG risk.
pubmed:affiliation
ChanTest Inc, ChanXpress Inc, Cleveland, OH, 44128, USA. bwible@chantest.com
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Evaluation Studies, Research Support, N.I.H., Extramural